BofA raised the firm’s price target on Danaher to $270 from $258 and keeps a Neutral rating on the shares after the company reported Q1 results ahead of expectations, with the firm highlighting “broad strength.” All in, the Q1 report shows “encouraging progress” from Danaher, but the firm awaits a broader and more consistent recovery in key markets beyond Bioprocessing, the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DHR:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue